Exelon® helps Alzheimer's disease patients to maintain greater independence
New findings suggest Exelon® significantly reduces decline in performance of activities of daily living in moderate to moderately severe Alzheimer's disease
Basel, 3 April 2003 - Therapy with Exelon (rivastigmine) helps patients with moderate to moderately severe Alzheimer's disease (AD) to maintain greater independence, according to an analysis of nearly 1500 patients.
Please find press release under the following link
Exelon helps Alzheimer's disease patients to maintain greater independence
| Source: Novartis Pharma AG
Attachments
Press Release Actions
Recommended Reading
-
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to...
Read More -
NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results...
Read More